HMNC Brain Health
Isabel Schwienbacher has a strong background in clinical science and pharmacology. Isabel worked at HMNC Brain Health as a Senior Director of Clinical Science since July 2021. Prior to that, they served as a Project Manager and Pharmacologist at the same company from January 2016 to June 2021. Before joining HMNC Brain Health, Isabel was the Head of Pharmacology at Acousia Therapeutics from April 2014 to December 2015. Isabel also worked at Merz Pharma as a Translational Medicine Expert from July 2013 to March 2014 and as a Section Head from February 2010 to June 2013. Isabel began their career as a Postdoc at Boehringer Ingelheim from 2005 to 2008.
Isabel Schwienbacher completed their education from 1994 to 2005 at the University of Tübingen. Isabel obtained a Doctorate degree in Biology-Neurosciences during this period.
This person is not in any offices
HMNC Brain Health
HMNC Brain Health develops patented genetic tests and combines those with innovative exclusively in-licensed medications, resulting in precise therapies for depression and other neuropsychiatric disorders.Founded in 2010, the privately held biotech company combines the development of machine learning-enabled companion diagnostics with specifictherapeutics to personalize the treatment of neuropsychiatric disorders with a focus on depression. The ultimate goal is to improve the lives of patients by developing highly disruptive solutions for their high unmet medical needs. HMNC Brain Health strives to reduce not only the immense individual burden but also the societal impact of these diseases.